Form 4: Palvella Therapeutics Officer Acquires Stock Options
SEC Form 4 Filing
Jeffrey S. Martini, Chief Scientific Officer of Palvella Therapeutics, acquires incentive and non-qualified stock options.
Summary
- On February 5, 2025, Jeffrey S. Martini, Chief Scientific Officer of Palvella Therapeutics, acquired incentive stock options for 5,373 shares and non-qualified stock options for 123,559 shares.
- The exercise price for both types of options is $14.76.
- The options vest in equal monthly tranches over 48 months and expire on February 5, 2035.
- Following the transaction, Martini directly owns 5,373 incentive stock options and 123,559 non-qualified stock options.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't convey any positive or negative sentiment about the company's performance or prospects.
Future Outlook
NA
Industry Context
This Form 4 filing is a routine disclosure of stock option grants to a company officer, which is a common practice in publicly traded companies to incentivize and retain key personnel.
Key Dates
| Date | Description |
|---|---|
| 02/05/2025 | Date of the stock option transaction |
| 02/05/2035 | Expiration date of the stock options |
| 02/07/2025 | Date of signature for the Form 4 filing |
Keywords
stock options, Palvella Therapeutics, insider trading, Form 4, Jeffrey S. Martini, Chief Scientific Officer, equity, PVLA
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.